Chimeric Therapeutics is trading at A$0.04, down 12.50%, with no confirmed company-specific catalyst identified for August 17, 2026.
- Recent announcements include A$1.62 million in R&D-tax funding, but they predate the decline.
- Broader market indices were broadly flat, providing no clear global explanation.
- Available coverage identifies no fresh announcement or trading-volume catalyst.